STOCK TITAN
  1. Home
  2. News
  3. VOR

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on August 8-9, 2023, at Lotte Palace Hotel in New York, NY.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow Healthcare Conference.

Wedbush PacGrow Healthcare Conference
1x1 Investor Meetings: August 8-9, 2023
Location: Lotte Palace Hotel, New York, NY

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


The company hosting the investor meetings is Vor Bio.

The 2023 Wedbush PacGrow Healthcare Conference will take place on August 8-9, 2023, at Lotte Palace Hotel in New York, NY.

The stock symbol of Vor Bio is Nasdaq: VOR.
Stock VOR logo
Vor Biopharma Inc

NASDAQ:VOR

VOR Rankings

#4162 Ranked by Market Cap
#4827 Ranked by Stock Gains
N/A Ranked by Dividends

VOR Latest News

Apr 1, 2024
Vor Bio to Participate in Upcoming Investor Conferences
Mar 20, 2024
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Mar 5, 2024
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 4, 2024
Vor Bio to Participate in Upcoming Investor Conferences
Feb 7, 2024
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

VOR Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About VOR

vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar